Skip to main content
. 2020 Jun 18;15(6):e0232870. doi: 10.1371/journal.pone.0232870

Table 3. Models for Δ4SC velocity in each data source.

Tadalafil DMD Trial Placebo Arm (n = 92) Leuven (n = 235) CCHMC (n = 543)
Base model Full model Base model Full model Base model Full model
Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI) Coefficient (95% CI)
Intercept -1 (-1.88, -0.13)* 5.53 (-0.07, 11.13) 0.98 (0.66, 1.29) 0.74 (-3.19, 4.66) 0.77 (0.55, 0.99)*** 3.02 (1.15, 4.89)**
Age (years) 0.03 (-0.02, 0.08) 0.04 (-0.02, 0.09) -0.08 (-0.11, -0.05)*** -0.03 (-0.07, 0.01) -0.06 (-0.08, -0.04)*** -0.05 (-0.09, -0.02)**
Steroids ≥ 1 year 1 vs. 0 0.26 (-0.05, 0.56) 0.42 (0.16, 0.69)** -0.15 (-0.33, 0.03) -0.29 (-0.47, -0.11)** -0.16 (-0.28, -0.04)** -0.24 (-0.37, -0.10)***
Timed 4-stair climb velocity 0.29 (-0.09, 0.66) -0.17 (-0.66, 0.31) -0.16 (-0.25, -0.07)*** -0.6 (-0.74, -0.46)*** -0.12 (-0.16, -0.07)*** -0.42 (-0.50, -0.34)***
Current deflazacort 1 vs. 0 0.16 (-0.01, 0.33) 0.16 (-0.02, 0.34) 0.01 (-0.12, 0.14)
Timed 10-meter walk/run velocity 0.22 (-0.07, 0.50) 0.27 (0.17, 0.37)*** -
Timed rise from supine velocity 1.41 (0.25, 2.56)* 1.83 (1.13, 2.53)*** -
Timed 30-foot walk/run velocity - - - - 0.13 (0.08, 0.18)***
Timed sit to stand velocity - - - - 0.72 (0.31, 1.13)***
BMI (kg/m2) -0.19 (-0.33, -0.05)** 0.02 (-0.08, 0.12) -0.1 (-0.14, -0.05)***
Height (cm) -0.05 (-0.10, -0.01)* -0.01 (-0.04, 0.03) -0.02 (-0.04, -0.01)**
Weight (kg) 0.11 (0.03, 0.20)** -0.01 (-0.06, 0.05) 0.06 (0.03, 0.08)***
Model R2 (adjusted R2) 0.08 (0.05) 0.29 (0.21) 0.17 (0.16) 0.36 (0.33) 0.16 (0.16) 0.30 (0.29)
RMSE 0.39 0.35 0.59 0.52 0.51 0.47

Δ4SC, annualized change in 4-stair climb; BMI, body mass index; CCHMC, Cincinnati Children's Hospital Medical Center; CI, confidence interval; cm, centimeters; kg, kilograms; m2, meters squared; n, number of participants; RMSE, root-mean squared error. Statistical significance: *** p < 0.001, ** p < 0.01, * p <0.05